Skip to main content

Advertisement

SpringerLink
Log in

Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma

  • Laboratory Investigation - Human/Animal Tissue
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The most effective chemotherapeutic for glioblastoma (GBM) is the DNA alkylating agent temozolomide (TMZ). In a recent study by Hegi et al. benefit from TMZ was significantly associated with methylation of the promoter of the O6-methylguanine-DNA methyltransferase (MGMT) gene; however, the correlation was imperfect. Some patients with methylated tumors were short survivors and others with unmethylated tumors were long survivors. These exceptions have raised the possibility that TMZ response might be influenced by non-MGMT mechanisms. The effect of p53 status on response to TMZ was explored in traditional glioma cell lines (U87MG, U251MG, U343MG, U373MG, SF767, LN443 and LNZ308) and brain tumor initiating cells (BTICs—BT012, BT025, BT042, BT048, BT060 and BT069) in two ways: (1) inhibition of p53 by RNAi and (2) sensitivity in relation to intrinsic p53 status, either wild-type or mutant. Traditional glioma cell lines that did not express a functional p53 were significantly more sensitive to TMZ than cell lines with functionally intact wild-type p53 expression. Altered p53 expression or function had only minor effects on TMZ sensitivity in BTICs and tended to decrease sensitivity to TMZ. RNAi specific for p53 had little effect on sensitivity in p53 null glioma cells. Absence of a functional p53 increases TMZ sensitivity in traditional glioma cell lines, an effect that is independent of MGMT status, and not seen in BTICs. P53 status may influence response to TMZ in differentiated cells in a GBM with a negligible affect on its initiating cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  CAS  PubMed  Google Scholar 

  2. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003

    Article  CAS  PubMed  Google Scholar 

  3. Olsson M, Lindahl T (1980) Repair of alkylated DNA in Escherichia coli. Methyl group transfer from O6-methylguanine to a protein cysteine residue. J Biol Chem 255:10569–10571

    CAS  PubMed  Google Scholar 

  4. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, Iafrate AJ, Louis DN (2007) Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 13:2038–2045

    Article  CAS  PubMed  Google Scholar 

  5. Danam RP, Howell SR, Brent TP, Harris LC (2005) Epigenetic regulation of O6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins. Mol Cancer Ther 4:61–69

    CAS  PubMed  Google Scholar 

  6. Everhard S, Tost J, El Abdalaoui H, Criniere E, Busato F, Marie Y, Gut IG, Sanson M, Mokhtari K, Laigle-Donadey F, Hoang-Xuan K, Delattre JY, Thillet J (2009) Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neurooncology 11:348–356

    CAS  Google Scholar 

  7. Nutt CL, Chambers AF, Cairncross JG (1996) Wild-type p53 renders mouse astrocytes resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea despite the absence of a p53-dependent cell cycle arrest [corrected]. Cancer Res 56:2748–2751

    CAS  PubMed  Google Scholar 

  8. Xu GW, Nutt CL, Zlatescu MC, Keeney M, Chin-Yee I, Cairncross JG (2001) Inactivation of p53 sensitizes U87MG glioma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 61:4155–4159

    CAS  PubMed  Google Scholar 

  9. Xu GW, Mymryk JS, Cairncross JG (2005) Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide. Int J Cancer 116:187–192

    Article  CAS  PubMed  Google Scholar 

  10. Hirose Y, Berger MS, Pieper RO (2001) p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61:1957–1963

    CAS  PubMed  Google Scholar 

  11. Dinca EB, Lu KV, Sarkaria JN, Pieper RO, Prados MD, Haas-Kogan DA, Vandenberg SR, Berger MS, James CD (2008) p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res 68:10034–10039

    Article  CAS  PubMed  Google Scholar 

  12. Kelly JJ, Stechishin O, Chojnacki A, Lun X, Sun B, Senger DL, Forsyth P, Auer RN, Dunn JF, Cairncross JG, Parney IF, Weiss S (2009) Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens. Stem Cells 27(8):1722–1733

    Article  CAS  PubMed  Google Scholar 

  13. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821–9826

    Article  CAS  PubMed  Google Scholar 

  14. Back SA, Khan R, Gan X, Rosenberg PA, Volpe JJ (1999) A new alamar blue viability assay to rapidly quantify oligodendrocyte death. J Neurosci Methods 91:47–54

    Article  CAS  PubMed  Google Scholar 

  15. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, de Tribolet N, Cavenee WK (1994) Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54:649–652

    PubMed  Google Scholar 

  16. Asaoka K, Tada M, Sawamura Y, Ikeda J, Abe H (2000) Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor. J Neurosurg 92:1002–1008

    Article  CAS  PubMed  Google Scholar 

  17. Xu GW, Mymryk JS, Cairncross JG (2005) Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin. J Neurooncol 74:141–149

    Article  CAS  PubMed  Google Scholar 

  18. Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, Dugan M, Batra V, Cutler D (1999) Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81:1022–1030

    Article  CAS  PubMed  Google Scholar 

  19. Rao DD, Senzer N, Cleary MA, Nemunaitis J (2009) Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development. Cancer Gene Ther 16(11):807–809

    Article  CAS  PubMed  Google Scholar 

  20. Blough MD, Zlatescu MC, Cairncross JG (2007) O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells. Cancer Res 67:580–584

    Article  CAS  PubMed  Google Scholar 

  21. Singh SK, Clarke ID, Hide T, Dirks PB (2004) Cancer stem cells in nervous system tumors. Oncogene 23:7267–7273

    Article  CAS  PubMed  Google Scholar 

  22. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German glioma network. J Clin Oncol 27(34):5743–5750

    Article  CAS  PubMed  Google Scholar 

  23. Li S, Zhang W, Chen B, Jiang T, Wang Z (2009) Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy. Neurol Res. doi:10.1179/016164109X12478302362536

Download references

Acknowledgments

This work was supported by Alberta Heritage Foundation for Medical Research, Hotchkiss Brain Institute New Initiatives Fund and Alberta Cancer Foundation Chair in Brain Tumour Research.

Author information

Authors and Affiliations

  1. Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada

    Michael D. Blough, Morgan R. Westgate, John J. Kelly & J. Gregory Cairncross

  2. Clark H. Smith Brain Tumour Centre, University of Calgary, Calgary, AB, Canada

    Michael D. Blough, Desiree C. Beauchamp, Morgan R. Westgate & J. Gregory Cairncross

  3. Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada

    John J. Kelly & J. Gregory Cairncross

  4. Alberta Cancer Research Institute, University of Calgary, Calgary, AB, Canada

    Michael D. Blough, Desiree C. Beauchamp, Morgan R. Westgate & J. Gregory Cairncross

  5. Foothills Medical Centre, 1403 29th St NW, Calgary, AB, T2N 2T9, Canada

    J. Gregory Cairncross

Authors
  1. Michael D. Blough
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Desiree C. Beauchamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Morgan R. Westgate
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John J. Kelly
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Gregory Cairncross
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Gregory Cairncross.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blough, M.D., Beauchamp, D.C., Westgate, M.R. et al. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma. J Neurooncol 102, 1–7 (2011). https://doi.org/10.1007/s11060-010-0283-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-010-0283-9

Keywords

Search

Navigation